+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

  • PDF Icon


  • 269 Pages
  • April 2020
  • Region: Global
  • Arizton
  • ID: 5011311
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Get an in-depth analysis of COVID-19 impact on the global premature ejaculation market.

The premature ejaculation therapeutics market is expected to grow at a CAGR of over 8% during the period 2019–2025.

The global premature ejaculation (PE) therapeutics market is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.

Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market

The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:
  • High Demand for Topical Drug Therapies for PE Treatment
  • Low Effectiveness of Non-pharmacological PE Treatment
  • Increasing Awareness Campaigns and Initiatives for PE Treatment
  • Advances in PE Drug Formulation Technology

The study considers the present scenario of the premature ejaculation therapeutics market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Premature Ejaculation Therapeutics Market: Segmentation

This research report offers a detailed segmentation by drugs, ROA, and geography. The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.

The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products worldwide is the prime factor enhancing growth.

Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.

Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.

Market Segmentation by Drug Class
  • SSRIs
  • PDE5 Inhibitors
  • Anesthetic Agents
  • Others

Market Segmentation by ROA
  • Oral PE therapeutics
  • Topical PE therapeutics

Insights by Geography

North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.

The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.

A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region.

Market Segmentation by Geography

  • Spain
  • Germany
  • Italy
  • France
  • UK

North America
  • US
  • Canada

  • South Korea
  • China
  • Japan
  • Australia
  • India

Latin America
  • Brazil
  • Argentina
  • Mexico

  • Turkey
  • Saudi Arabia
  • South Africa
  • Iran

Insights by Vendors

The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.

Key Vendors
  • Absorption Pharmaceuticals
  • Innovus Pharmaceuticals
  • Pfizer
  • Plethora Solutions Holdings

Other Vendors
  • Bayer
  • Eli Lilly and Company
  • GlaxoSmithKline
  • MidasCare
  • Momentum Management
  • Pound International
  • Reckitt Benckiser Group
  • Recordati
  • Royalty Pharma
  • Shibari
  • The Menarini Group

Key Market Insights
The analysis of the premature ejaculation therapeutics market provides sizing and growth opportunities for the period 2020–2025.
  • Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
  • Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
  • Delivers a complete overview of segments and the regional outlook of the market.
  • Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Premature Ejaculation: An Overview
7.1.1 Definition
7.1.2 Disease Overview
7.1.3 Classification of Premature Ejaculation
7.1.4 Symptoms of PE
7.1.5 Etiology of Premature Ejaculation
7.1.6 Epidemiology
7.2 ISSN Guidelines On Premature Ejaculation
7.2.1 Disease Assessment
7.2.2 Treatment Options For Pe
8 Clinical Trial Landscape
8.1 Overview
8.1.1 Subjects Selection Criteria for PE Clinical Trials
8.1.2 Clinical Trial Data Evaluation Considerations
8.1.3 Clinical Trial Design Considerations for PE
8.2 Clinical Trial Endpoints
9 Pipeline Landscape
9.1 Overview
9.2 Key Pipeline Drug candidates
9.3 Key Pipeline Molecules
9.3.1 Epelsiban
9.3.2 IX-01
9.3.3 DA-8031
9.3.4 NH02D
9.4 Terminated/Withdrawn Drug Candidates
10 Market Opportunities & Trends
10.1 High Demand for Topical Drug Therapies for PE Treatment
10.2 Presence of High Unmet Demand
10.3 Advancements in PE Drug Formulation Technology
11 Market Growth Enablers
11.1 Rising Prevalence/Incidence of PE
11.2 Wide Accessibility of OTC Drugs & General Off-label Drugs for PE
11.3 Low effectiveness of Non-pharmacological PE Treatment
11.3.1 Major Drawbacks of Non-Pharmacological Treatments
11.4 Increasing Awareness Campaigns & Initiatives for PE Treatment
12 Market Restraints
12.1 Availability of Alternative Treatment Options for PE
12.2 Low Treatment-Seeking Patient Pool
12.3 Adverse Effects of PE Therapeutics
12.4 Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies
13 Market Landscape
13.1 Market Overview
13.2 Market Size & Forecast
13.3 Five Forces Analysis
13.3.1 Threat of New Entrants
13.3.2 Bargaining Power of Suppliers
13.3.3 Bargaining Power of Buyers
13.3.4 Threat of Substitutes
13.3.5 Competitive Rivalry
14 Drug Class
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 SSRIs
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 PDE5 Inhibitors
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Anesthetic Agents
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 Route of Administration
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Oral
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.4 Topical
15.4.1 Market Overview
15.4.2 Market Size & Forecast
16 Geography
16.1 Market Snapshot & Growth Engine
16.2 Overview
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Drug Class Segmentation
17.3.1 Market Snapshot & Growth Engine
17.4.1 US: Market Size & Forecast
17.4.2 Canada: Market Size & Forecast
18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Drug Class Segmentation
18.3.1 Market Snapshot & Growth Engine
18.4 Key Countries
18.4.1 Germany: Market Size & Forecast
18.4.2 UK: Market Size & Forecast
18.4.3 France: Market Size & Forecast
18.4.4 Italy: Market Size & Forecast
18.4.5 Spain: Market Size & Forecast
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Drug Class Segmentation
19.3.1 Market Snapshot & Growth Engine
19.4 Key Countries
19.4.1 Japan: Market Size & Forecast
19.4.2 India: Market Size & Forecast
19.4.3 China: Market Size & Forecast
19.4.4 Australia: Market Size & Forecast
19.4.5 South Korea: Market Size & Forecast
20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Drug Class Segmentation
20.3.1 Market Snapshot & Growth Engine
20.4 Key Countries
20.4.1 Brazil: Market Size & Forecast
20.4.2 Mexico: Market Size & Forecast
20.4.3 Argentina: Market Size & Forecast
21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Drug Class Segmentation
21.3.1 Market Snapshot & Growth Engine
21.4 Key Countries
21.4.1 Turkey: Market Size & Forecast
21.4.2 Saudi Arabia: Market Size & Forecast
21.4.3 South Africa: Market Size & Forecast
21.4.4 Iran: Market Size & Forecast
22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
22.2.1 Absorption Pharmaceuticals
22.2.2 Innovus Pharmaceuticals
22.2.3 Pfizer
22.2.4 Plethora Solutions
23 Key Company Profiles
23.1 Absorption Pharmaceuticals
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 Innovus Pharmaceuticals
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities
23.3 Pfizer
23.3.1 Business Overview
23.3.2 Product Offerings
23.3.3 Key Strategies
23.3.4 Key Strengths
23.3.5 Key Opportunities
23.4 Plethora Solutions Holdings
23.4.1 Business Overview
23.4.2 Product Offerings
23.4.3 Key Strategies
23.4.4 Key Strengths
23.4.5 Key Opportunities
24 Other Prominent Vendors
24.1 Bayer
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Eli Lilly and Company
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 GlaxoSmithKline
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 MidasCare
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 Momentum Management
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunities
24.6 Pound International
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 Reckitt Benckiser Group
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities
24.8 Recordati
24.8.1 Business Overview
24.8.2 Product Offerings
24.8.3 Key Strategies
24.8.4 Key Strengths
24.8.5 Key Opportunities
24.9 Royalty Pharma
24.9.1 Business Overview
24.9.2 Product Offerings
24.9.3 Key Strategies
24.9.4 Key Strengths
24.9.5 Key Opportunities
24.10 Shibari
24.10.1 Business Overview
24.10.2 Product Offerings
24.10.3 Key Strategies
24.10.4 Key Strengths
24.10.5 Key Opportunities
24.11 The Menarini Group
24.11.1 Business Overview
24.11.2 Product Offerings
24.11.3 Key Strategies
24.11.4 Key Strengths
24.11.5 Key Opportunities
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Drug Class
26.2 Route of Administration (RoA)
26.3 Geography
27 Appendix
27.1 Abbreviations

Companies mentioned

  • Absorption Pharmaceuticals
  • Innovus Pharmaceuticals
  • Pfizer
  • Plethora Solutions Holdings
  • Bayer
  • Eli Lilly and Company
  • GlaxoSmithKline
  • MidasCare
  • Momentum Management
  • Pound International
  • Reckitt Benckiser Group
  • Recordati
  • Royalty Pharma
  • Shibari
  • The Menarini Group


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.